Skip to main content
PRTA
NASDAQ Life Sciences

Prothena Discloses 100% Executive Bonuses Amidst $244M Loss, Faces Shareholder Say-on-Pay Vote

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.26
Mkt Cap
$498.493M
52W Low
$4.32
52W High
$13.52
52W Position info
114% above low
Off High info
32% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PRTA has more than doubled off its 52-week low of $4.32.

Summary

Prothena's definitive proxy statement reveals 100% executive bonus payouts for 2025 despite a $244.1 million net loss and workforce reduction, setting the stage for a critical shareholder vote on executive compensation.


Key Events · Corporate Governance and Compliance · PRTA

  • Executive Bonuses Paid at 100% Target Despite Significant Loss

    Named executive officers received 100% of their target annual cash bonuses for 2025, even as the company reported a $244.1 million net loss and implemented a 63% workforce reduction following a Phase 3 program discontinuation.

  • Shareholder Say-on-Pay Vote Follows Prior Dissatisfaction

    Shareholders will hold a non-binding advisory vote on executive compensation, a year after only 76% approved the 2024 compensation, prompting the company to engage with its largest shareholders.

  • Board to Reduce Size; Two Directors Nominated for Re-election

    Helen S. Kim is not standing for re-election, and the Board plans to reduce its size from eight to seven members. Shane M. Cooke and Dennis J. Selkoe are nominated for re-election to terms expiring in 2029.

  • Significant Equity Overhang Disclosed

    The company has 11,380,072 securities to be issued upon exercise of outstanding options, warrants, and rights, representing approximately 21.14% of current outstanding shares. An additional 5,400,701 shares are available for future issuance under equity plans, representing approximately 10.03% potential dilution.


Analysis · PRTA · Life Sciences

This definitive proxy statement outlines key proposals for the upcoming annual general meeting, including director elections and the advisory vote on executive compensation. The disclosure of 100% target bonus payouts for executive officers in 2025, despite a significant net loss of $244.1 million and a 63% workforce reduction, is a notable point of potential shareholder concern. This follows a lower 76% approval rate for the prior year's say-on-pay vote, indicating existing shareholder dissatisfaction with compensation practices. Additionally, the substantial equity overhang from outstanding options and shares available for future issuance represents a significant potential dilution for shareholders. Investors should closely monitor the outcome of the say-on-pay vote and any further shareholder engagement on compensation practices.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRTA was trading at $9.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $498.5M. The 52-week trading range was $4.32 to $13.52. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRTA - Latest Insights

PRTA
Nov 05, 2026, 5:55 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.17 info
Change: +$0.280 (+4%) info
Market Cap: $419.014M info
PRTA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.17 info
Change: +$0.280 (+4%) info
Market Cap: $419.014M info
PRTA
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.88
Real-time Price: $8.17 info
Change: -$0.710 (-8%) info
Market Cap: $419.014M info
PRTA
Aug 06, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.17 info
Change: -$0.410 (-5%) info
Market Cap: $419.014M info
PRTA
Aug 06, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.17 info
Change: -$0.410 (-5%) info
Market Cap: $419.014M info